An integrated in silico immuno-genetic analytical platform provides insights into COVID-19 serological and vaccine targets.
Genome Med
; 13(1): 4, 2021 01 07.
Article
in English
| MEDLINE | ID: covidwho-1059849
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
During COVID-19, diagnostic serological tools and vaccines have been developed. To inform control activities in a post-vaccine surveillance setting, we have developed an online "immuno-analytics" resource that combines epitope, sequence, protein and SARS-CoV-2 mutation analysis. SARS-CoV-2 spike and nucleocapsid proteins are both vaccine and serological diagnostic targets. Using the tool, the nucleocapsid protein appears to be a sub-optimal target for use in serological platforms. Spike D614G (and nsp12 L314P) mutations were most frequent (> 86%), whilst spike A222V/L18F have recently increased. Also, Orf3a proteins may be a suitable target for serology. The tool can accessed from http//genomics.lshtm.ac.uk/immuno (online); https//github.com/dan-ward-bio/COVID-immunoanalytics (source code).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
Type of study:
Diagnostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Genome Med
Year:
2021
Document Type:
Article
Affiliation country:
S13073-020-00822-6
Similar
MEDLINE
...
LILACS
LIS